Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis

Y. Qiu (Princeton, NJ, United States of America), R. Zhao (Princeton, NJ, United States of America), B. Elpers (Princeton, NJ, United States of America), Y. Wang (Ann Arbor, MI, United States of America), L. Xie (Ann Arbor, MI, United States of America), J. Tang (Ann Arbor, MI, United States of America), A. Fischer (Princeton, NJ, United States of America)

Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session: Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session type: E-poster session
Number: 1851

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Qiu (Princeton, NJ, United States of America), R. Zhao (Princeton, NJ, United States of America), B. Elpers (Princeton, NJ, United States of America), Y. Wang (Ann Arbor, MI, United States of America), L. Xie (Ann Arbor, MI, United States of America), J. Tang (Ann Arbor, MI, United States of America), A. Fischer (Princeton, NJ, United States of America). Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis. 1851

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: